Phase1 Syudy to Evaluate the Safety and PK/PD of Human Antithrombin III

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00846274
Recruitment Status : Completed
First Posted : February 18, 2009
Last Update Posted : February 18, 2009
Korea University Anam Hospital
Information provided by:
SK Chemicals Co.,Ltd.

Brief Summary:
To evaluate the PK/PD of single injected human ATIII Products, SKATIII and ATIII, phase1 study in healthy male subjects was designed

Condition or disease Intervention/treatment Phase
Healthy Biological: SK Antithrombin III Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Single-Dose, Open Label, Randomized Comparative Clinical Trial to Evaluate the Tolerability, Safety and PK/PD of Human ATIII Products, "SKATIII Injection" and"ATIII Injection" in Healthy Male Subjects
Study Start Date : October 2008
Primary Completion Date : December 2008
Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Antithrombin III Biological: SK Antithrombin III
Experimental: SK Antithrombin III Biological: SK Antithrombin III

Primary Outcome Measures :
  1. ATIII activity [ Time Frame: within 20min after injection ATIII ]

Secondary Outcome Measures :
  1. ATIII antigen [ Time Frame: within 20min after injection ATIII ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • ages 19 to 40
  • Body weight: More than 50kg
  • Healthy male subject

Exclusion Criteria:

  • Hb<14g/dL, Hct<42%
  • ATIII hypersensitivity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00846274

Korea, Republic of
SK chemicals
Seoul, Korea, Republic of
Sponsors and Collaborators
SK Chemicals Co.,Ltd.
Korea University Anam Hospital
Principal Investigator: Ji Young Park, MD,PhD Korea University Anam Hospital

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Clinical Research Team, SK Chemicals Co.,Ltd. Identifier: NCT00846274     History of Changes
Other Study ID Numbers: SKATIII_I_2007
First Posted: February 18, 2009    Key Record Dates
Last Update Posted: February 18, 2009
Last Verified: February 2009

Keywords provided by SK Chemicals Co.,Ltd.:
Healthy Male subjects

Additional relevant MeSH terms:
Antithrombin III
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action